In late 2017, LLNL licensed a biomedical technology called nanolipoprotein particles (NLPs), which can deliver vaccines and drugs inside the cells in the human body, to Ann Arbor, Michigan-based EVOQ Therapeutics. EVOQ Therapeutics has announced two major agreements with Gilead Sciences Inc. and Amgen Inc. to work on the preclinical development of novel medicines to combat autoimmune diseases.
Technology Portfolio
